Ar-42 (DrugBank: AR-42)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
34 | Neurofibromatosis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02282917 (ClinicalTrials.gov) | September 2015 | 31/10/2014 | Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | Vestibular Schwannoma;Meningioma;Acoustic Neuroma;Neurofibromatosis Type 2 | Drug: AR-42 | Massachusetts Eye and Ear Infirmary | Johns Hopkins University;Mayo Clinic;Stanford University;Ohio State University;Nationwide Children's Hospital | Active, not recruiting | 18 Years | N/A | All | 5 | Early Phase 1 | United States |